Photo by nci from unsplash
The prevalence of obesity in U.S. adults is 38% and class III obesity (BMI ≥40 kg/m2) approaches 8%, many have comorbid atrial fibrillation (AF). Recent recommendations caution against novel oral… Click to show full abstract
The prevalence of obesity in U.S. adults is 38% and class III obesity (BMI ≥40 kg/m2) approaches 8%, many have comorbid atrial fibrillation (AF). Recent recommendations caution against novel oral anticoagulant (NOAC) use for thromboembolic (TE) prophylaxis in obese patients and advise against use
Keywords:
atrial fibrillation;
novel oral;
obese patients;
thromboembolic prophylaxis;
prophylaxis obese
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!